WuXi XDC announces mechanical completion of Singapore site

WuXi XDC Cayman, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) said that the mechanical completion of its manufacturing site at Tuas Biomedical Park in Singapore has been successfully achieved.

The Singapore site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025 and Good Manufacturing Practice (GMP) manufacturing in 2026. The site will offer comprehensive production capabilities from the preclinical stage to commercialization.

According to current capacity plan, the site is anticipated to create more than 500 job opportunities and over 100 people have joined our company so far.

Dr. Jimmy Li, CEO of WuXi XDC, stated, “The rapid mechanical completion of our Singapore site marks a critical pillar in our ‘Global Dual-Sourcing’ strategy. This global site will form a worldwide network alongside our Wuxi, Changzhou, and Shanghai sites, delivering end-to-end CRDMO services to global customers. This accomplishment showcases the full support of the partners for the construction of Singapore site, our deep understanding of global market demands, our ability to respond swiftly and the robust execution capabilities of our team. Looking ahead, we remain committed to advancing our one-stop model and global supply network, collaborating with global partners to promote the diversified and sustainable development of bioconjugates.”